Braeburn’s CAM2038 meets in Phase III for chronic low back pain
Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) said CAM2038 met the primary endpoint in the Phase III HS-16-555 trial to treat moderate to severe chronic low back pain in patients previously on long-term daily opioid therapy. CAM2038 significantly reduced average pain intensity from baseline to week 12 vs. placebo on an 11-point numeric rating scale (NRS) (p<0.001). CAM2038 also met the secondary endpoint of reducing worst pain intensity vs. placebo (p<0.001).
The double-blind, U.S. trial enrolled about 340 patients who required continuous around-the-clock opioid treatment with an equivalent morphine dose of at least 40 mg to receive placebo or once-weekly or once-monthly CAM2038 for 12 weeks...
BCIQ Target Profiles